| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS10016591 | HBV | ENSG00000131730.16 | protein_coding | CKMT2 | No | No | 1160 | P17540 |
| TVIS10030359 | HBV | ENSG00000131730.16 | protein_coding | CKMT2 | No | No | 1160 | P17540 |
| TVIS30088351 | HIV | ENSG00000131730.16 | protein_coding | CKMT2 | No | No | 1160 | P17540 |
| TVIS20043487 | HPV | ENSG00000131730.16 | protein_coding | CKMT2 | No | No | 1160 | P17540 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | CKMT2 |
|---|---|
| DrugBank ID | DB00148 |
| Drug Name | Creatine |
| Target ID | BE0000410 |
| UniProt ID | P17540 |
| Regulation Type | ligand |
| PubMed IDs | 17139284; 17016423; 10567223; 8399219; 9642223; 1731757 |
| Citations | Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.@@Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.@@Koufen P, Ruck A, Brdiczka D, Wendt S, Wallimann T, Stark G: Free radical-induced inactivation of creatine kinase: influence on the octameric and dimeric states of the mitochondrial enzyme (Mib-CK). Biochem J. 1999 Dec 1;344 Pt 2:413-7.@@Wyss M, James P, Schlegel J, Wallimann T: Limited proteolysis of creatine kinase. Implications for three-dimensional structure and for conformational substrates. Biochemistry. 1993 Oct 12;32(40):10727-35.@@Stachowiak O, Dolder M, Wallimann T, Richter C: Mitochondrial creatine kinase is a prime target of peroxynitrite-induced modification and inactivation. J Biol Chem. 1998 Jul 3;273(27):16694-9.@@Wallimann T, Wyss M, Brdiczka D, Nicolay K, Eppenberger HM: Intracellular compartmentation, structure and function of creatine kinase isoenzymes in tissues with high and fluctuating energy demands: the 'phosphocreatine circuit' for cellular energy homeostasis. Biochem J. 1992 Jan 1;281 ( Pt 1):21-40. |
| Groups | Approved; Investigational; Nutraceutical |
| Direct Classification | Alpha amino acids and derivatives |
| SMILES | CN(CC(O)=O)C(N)=N |
| Pathways | Guanidinoacetate Methyltransferase Deficiency (GAMT Deficiency); Hyperornithinemia with Gyrate Atrophy (HOGA); Hyperprolinemia Type II; 3-Phosphoglycerate Dehydrogenase Deficiency; Non-Ketotic Hyperglycinemia; L-Arginine:Glycine Amidinotransferase Deficiency; Hyperornithinemia-Hyperammonemia-Homocitrullinuria [HHH-syndrome]; Arginine: Glycine Amidinotransferase Deficiency (AGAT Deficiency); Prolidase Deficiency (PD); Glycine and Serine Metabolism; Hyperglycinemia, Non-Ketotic; Dimethylglycine Dehydrogenase Deficiency; Creatine Deficiency, Guanidinoacetate Methyltransferase Deficiency; Ornithine Aminotransferase Deficiency (OAT Deficiency); Hyperprolinemia Type I; Dihydropyrimidine Dehydrogenase Deficiency (DHPD); Arginine and Proline Metabolism; Prolinemia Type II; Sarcosinemia |
| PharmGKB | PA164778930 |
| ChEMBL | CHEMBL283800 |
